VolitionRx Limited (NYSE: VNRX), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent with Missionpharma A/S, a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition's prototype Lateral Flow Technology for NETosis.
Chief Operating Officer Gaetan Michel, commented:
"We recently announced a major technical milestone: results utilizing our lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients, thereby expanding beyond centralized laboratory testing. This finger prick sample test could be used worldwide, beyond solely high-income countries.
"The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation, and we believe its use will cover a broad range of diseases including sepsis and septic shock.
"By enabling decentralized testing, our total addressable market expands, and, with the help of Missionpharma, we hope to accelerate commercialization and market access, particularly in resource-constrained countries and humanitarian emergency settings."
VNRX shares ducked $0.004, or 2.1%, to 17 cents.
Related Stories
